Spontaneous rectus sheath hematoma during rivaroxaban therapy

Rivaroxaban is an oral anticoagulant agent that directly inhibits Factor Xa and interrupts both the intrinsic and extrinsic pathway of the coagulation cascade and is currently indicated for use in patients for atrial fibrillation and prophylaxis of deep venous thrombosis. The present case reports of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kocayigit, Ibrahim, Can, Yusuf, Sahinkus, Salih, Aydın, Ercan, Vatan, Mehmet Bulent, Kılıc, Harun, Gunduz, Huseyin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Drug Watch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4071715/
https://www.ncbi.nlm.nih.gov/pubmed/24987185
http://dx.doi.org/10.4103/0253-7613.132193
Descripción
Sumario:Rivaroxaban is an oral anticoagulant agent that directly inhibits Factor Xa and interrupts both the intrinsic and extrinsic pathway of the coagulation cascade and is currently indicated for use in patients for atrial fibrillation and prophylaxis of deep venous thrombosis. The present case reports of spontaneous rectus sheath hematoma during rivaroxaban therapy for atrial fibrillation in a 75-year-old woman.

Ejemplares similares